# External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)

> **NCT05537662** · NA · RECRUITING · sponsor: **Abbott Medical Devices** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Pain

## Interventions

- **DEVICE:** Standard of care neuromodulation therapy (SCS or DRG)

## Key facts

- **NCT ID:** NCT05537662
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-06
- **Primary completion:** 2025-01
- **Final completion:** 2025-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05537662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05537662, "External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05537662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*